| Anil Pathare, MD,PhD | |
| +968-99384951 | |
| [email protected];[email protected] |
| Salam Alkindi, MD, FRCPI | |
| +968-99353188 | |
| [email protected];[email protected] |
1 Oman site
13 to 70 Years
Phase 3
Interventional
All
Dietary Supplement
Unknown
140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD
patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan
Qaboos University Hospital [SQUH] haematology specialty clinics. Patients will be randomized
in a 1:1 ratio to receive placebo or Omega-3 for 52 weeks. The aim is to investigate the
therapeutic potential of omega-3 fatty acids in the prevention of vaso-occlusive crisis in
Omani patients with sickle cell disease[SCD].
– Moderate to severe Sickle cell disease patients.
– Patients already receiving Hydroxyurea[HU] are eligible for the study.
– Patients able and willing to comply with the procedures in the study protocol.
– Acute episodes (infection, vaso-occlusive crises (VOC), acute chest syndrome (ACS),
stroke, priapism, splenic sequestration) in the past one month before enrolment.
– Previous stroke, and other co-morbid diseases like Essential Hypertension,
Cardiomyopathy and Heart failure, Diabetes, Chronic Renal Failure.
– Patients with a history of adverse reaction to omega-3 fatty acid supplementation.
– Blood transfusion in the previous 3 months.